

# Takushi Yasuda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9108483/publications.pdf>

Version: 2024-02-01

42  
papers

761  
citations

759233

12  
h-index

552781

26  
g-index

43  
all docs

43  
docs citations

43  
times ranked

811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study. <i>Gastric Cancer</i> , 2022, 25, 430-437.	5.3	15
2	Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 975-983.	1.9	4
3	Circular Stapler Method for Avoiding Stricture of Cervical Esophagogastric Anastomosis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 725-732.	1.7	5
4	Perioperative Ghrelin Administration Attenuates Postoperative Skeletal Muscle Loss in Patients Undergoing Esophagectomy for Esophageal Cancer: Secondary Analysis of a Randomized Controlled Trial. <i>Annals of Surgical Oncology</i> , 2022, 29, 3604-3612.	1.5	6
5	ASO Author Reflections: Can Perioperative Ghrelin Administration Inhibit Postoperative Muscle Mass Loss in Esophageal Cancer Patients?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	ASO Visual Abstract: Perioperative Ghrelin Administration Attenuates Postoperative Skeletal Muscle Loss in Patients Undergoing Esophagectomy for Esophageal Cancer—Secondary Analysis of a Randomized, Controlled Trial. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
7	Comparison of synbiotics combined with enteral nutrition and prophylactic antibiotics as supportive care in patients with esophageal cancer undergoing neoadjuvant chemotherapy: A multicenter randomized study. <i>Clinical Nutrition</i> , 2022, 41, 1112-1121.	5.0	8
8	Salvage Surgery for Recurrent Disease after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5657-5665.	1.5	1
9	Real-world treatment patterns and outcomes in Japanese patients with cervical esophageal cancer. <i>Esophagus</i> , 2022, , .	1.9	2
10	Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors. <i>Annals of Surgery</i> , 2021, 274, 120-127.	4.2	138
11	Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 75-82.	2.4	16
12	Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. <i>Esophagus</i> , 2021, 18, 825-834.	1.9	14
13	Comparison of Aggressive Planned Salvage Surgery Versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6366-6375.	1.5	6
14	Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3666-3682.	6.4	4
15	Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer. <i>Clinical Nutrition</i> , 2021, 40, 4380-4385.	5.0	18
16	OSK-0028 in Patients With Esophageal Cancer Undergoing Esophagectomy: A Double-blind, Randomised Controlled Trial. <i>Anticancer Research</i> , 2021, 41, 3875-3884.	1.1	3
17	A comparative study of the lengths of different reconstruction routes used after thoracic esophagectomy. <i>Esophagus</i> , 2021, 18, 468-474.	1.9	5
18	Risk Factors and Prognostic Impact of Mediastinal Lymph Node Metastases in Patients with Esophagogastric Junction Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4433-4440.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	12
20	Whole genome sequencing analysis identifies recurrent structural alterations in esophageal squamous cell carcinoma. <i>PeerJ</i> , 2020, 8, e9294.	2.0	12
21	Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, Sâ€, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 56-63.	1.7	7
22	Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 73-80.	2.2	9
23	Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial. <i>Anticancer Research</i> , 2018, 38, 5975-5981.	1.1	12
24	Novel esophageal reconstruction technique via transmediastinal route from posterior to anterior mediastinum after esophagectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 859-866.	0.8	3
25	Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2127-2128.	1.5	5
26	Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. <i>Oncology</i> , 2017, 92, 101-108.	1.9	34
27	Randomized study of the clinical effects of "3 fatty acid" containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. <i>Nutrition</i> , 2017, 33, 204-210.	2.4	43
28	Pedicle posterior pericardial repair of tracheoesophageal fistula after chemoradiotherapy for esophageal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, e95-e97.	0.8	6
29	A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential Sâ€ plus intravenous paclitaxel for serosaâ€positive gastric cancer. <i>Journal of Surgical Oncology</i> , 2015, 111, 1041-1046.	1.7	11
30	A novel technique for securing tracheal blood supply in salvage anterior mediastinal tracheostomy. <i>International Journal of Surgery Case Reports</i> , 2015, 14, 112-116.	0.6	0
31	A newly modified esophagogastrostomy with a reliable angle of His by placing a gastric tube in the lower mediastinum in laparoscopy-assisted proximal gastrectomy. <i>Gastric Cancer</i> , 2015, 18, 850-858.	5.3	33
32	Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2599-2607.	1.5	19
33	Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with 18F-fluorodeoxyglucose positron emission tomography-positive lymph nodes. <i>Surgery Today</i> , 2015, 45, 335-345.	1.5	5
34	A prospective observational study on chemotherapy-induced nausea and vomiting for esophageal cancer patients in Japan.. <i>Journal of Clinical Oncology</i> , 2014, 32, 135-135.	1.6	0
35	Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. <i>Molecular and Clinical Oncology</i> , 2013, 1, 521-526.	1.0	12
36	Relationship between Immunological Parameters and the Severity of Neutropenia and Effect of Enteral Nutrition on Immune Status during Neoadjuvant Chemotherapy on Patients with Advanced Esophageal Cancer. <i>Oncology</i> , 2012, 83, 91-100.	1.9	19

#	ARTICLE	IF	CITATIONS
37	Phase I clinical trial of vaccination with URLC10-derived peptide for patients with advanced esophageal cancer. <i>Esophagus</i> , 2012, 9, 105-112.	1.9	2
38	Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. <i>Clinical Nutrition</i> , 2012, 31, 330-336.	5.0	80
39	Esophageal Reconstruction Using a Pedicled Jejunum with Microvascular Augmentation. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2011, 17, 103-109.	0.8	28
40	Esophageal reconstruction with colon tissue. <i>Surgery Today</i> , 2011, 41, 745-753.	1.5	41
41	Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery. <i>Esophagus</i> , 2011, 8, 81-87.	1.9	11
42	Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus. <i>Oncology</i> , 2011, 80, 307-313.	1.9	95